Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT00375830
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Professor of Radiology (Nuclear Medicine)
Professor of Radiology (Cardiovascular Imaging), Emeritus
William R. Brody Professor of Pediatric Radiology and Child Health
All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).
INCLUSION CRITERIA
- ≥ 18 years old at the time of the drug administration
- ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
(PSA) > 10 micrograms/L OR recurrent breast or prostate cancer
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (about one hour)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants that contraindicate MRI
- Renal function impairment that contraindicates MRI
drug: Gadopentetate dimeglumine
drug: Gadofosveset
drug: Gadobutrol
procedure: Bone scan
procedure: Positron Emission Tomography (PET) scan
drug: 18F-Fludeoxyglucose (18F-FDG)
procedure: Computed Tomography (CT) scan
drug: 18F-Sodium Fluoride (18F-NaF)
procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
drug: 99mTc-methyl diphosphonate
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061